New drugs help Novartis shrug off Gleevec competition - PMLiVE
Patients or patents? | Mint
Sanofi schmiedet millionenschwere Diabetes-Allianz mit Google | Reuters
Cipla Signs Licence Agreement with Novartis AG; Will Manufacture Type-2 Diabetes Medicine From 2026 - Bharat Express
Novartis' Patent On Diabetes Drug Vildagliptin Expires Tomorrow, Prices To Fall By 60%
Price of key diabetes drug may crash as Novartis risks losing patent
Cancer Drug for Diabetes? | Science | AAAS
Novartis heart-failure med Entresto cuts A1c, insulin starts in diabetics: analysis | Fierce Pharma
NPPA: NPPA to look into diabetes drug price-fixing allegations - The Economic Times
Novartis Drugs For Diabetes « AUSPIC
Novartis reaches $678 million settlement of U.S. fraud lawsuit
Novartis Drugs For Diabetes – Eunice Kennedy Shriver Center
Diabetes Drugs Market to Reach US$ 78,261.7 Mn by 2026,
Cipla inks licensing pact with Novartis to manufacture, mkt diabetes drug
Chamberlain PR wins Novartis diabetes drug brief following competitive pitch | PR Week
Natco challenges Novartis; claims right to manufacture diabetes drug - Times of India
Cipla Signs Licence Agreement With Novartis Ag To Manufacture And Market Type-2 Diabetes Medicine
NeoBiocon partners Novartis to launch diabetes drugs in UAE - The Economic Times
NeoBiocon Partners Novartis to Launch Diabetes Drugs in UAE
Novartis Diabetes Triple Drug Combination Deemed 'Irrational' In India :: Pink Sheet
After trial flop, EU officials taking a closer look at Novartis' Adakveo
Novartis sues Biocon over anti-diabetes drug vildagliptin: Bitter pill? – Spicyip
Diabetes Drugs Market to See Huge Demand by 2030: Takeda, Novartis, Dongbao Pharmaceutical
Novartis Reveals New Entresto Data at ACC 2017 - Drug Discovery and Development
2 Diabetes Drugs May Lower Blood Sugar - CBS News
Novartis files patent suit against Biocon over Galvus - BusinessToday
Cipla, Novartis AG ink agreement on diabetes therapy Galvus - The Hindu BusinessLine
Cipla, Novartis team up to make, market anti-diabetic drug - HealthQuill
Novartis Bets $3.5 Billion on Chinook's Rare Disease Drugs
